Evaxion A/S
EVAX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001828253
No open-market purchases or sales by Evaxion A/S insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $4.93M in total; no superinvestor holds it.
Holders of 5% or more of EVAX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Evaxion A/S, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Merck & Co., Inc. | 13G/A | 19.96%63.0M shares | – | Feb 3, 20251 filing | Feb 3, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on Evaxion A/S, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 15, 20253:35 PM ET | Armistice Capital, LLCand 1 other | 13G/A | 4.99%310.4K shares | −5.00 ppfrom 9.99%Below 5% | Mar 31, 2025 | SEC |
| Feb 14, 20255:44 PM ET | Armistice Capital, LLCand 1 other | 13G/A | 9.99%639.3K shares | – | Dec 31, 2024 | SEC |
| Feb 3, 20254:15 PM ET | Merck & Co., Inc.and 2 others | 13G/A | 19.96%63.0M shares | – | Jan 31, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Evaxion A/S shares.
No Form 144 notices for Evaxion A/S are on file.